NO135892B - - Google Patents
Download PDFInfo
- Publication number
- NO135892B NO135892B NO4558/71A NO455871A NO135892B NO 135892 B NO135892 B NO 135892B NO 4558/71 A NO4558/71 A NO 4558/71A NO 455871 A NO455871 A NO 455871A NO 135892 B NO135892 B NO 135892B
- Authority
- NO
- Norway
- Prior art keywords
- saxitoxin
- lidocaine
- bupivacaine
- injection
- concentration
- Prior art date
Links
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 claims description 29
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 claims description 29
- 229960004194 lidocaine Drugs 0.000 claims description 27
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 15
- 229960003150 bupivacaine Drugs 0.000 claims description 15
- 239000003589 local anesthetic agent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 11
- 230000003444 anaesthetic effect Effects 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 210000002414 leg Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010039757 Scrotal pain Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- CDJDGQRYHDBSKC-UHFFFAOYSA-N 2,3,4,5,6,7,8,9-octahydro-1h-purine Chemical group C1NCNC2NCNC21 CDJDGQRYHDBSKC-UHFFFAOYSA-N 0.000 description 1
- -1 2-imino-8-amino-6-methyl-3-β-carboxyethylpurine Chemical compound 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 241001238245 Saxidomus Species 0.000 description 1
- 208000004891 Shellfish Poisoning Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001432 effect on motor function Effects 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000238 shellfish toxin Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10994271A | 1971-01-26 | 1971-01-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135892B true NO135892B (es) | 1977-03-14 |
| NO135892C NO135892C (no) | 1978-05-16 |
Family
ID=22330411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO4557/71A NO135891C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
| NO4558/71A NO135892C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO4557/71A NO135891C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
Country Status (18)
| Country | Link |
|---|---|
| AT (2) | AT310939B (es) |
| AU (1) | AU465875B2 (es) |
| BE (2) | BE776769A (es) |
| BR (2) | BR7108428D0 (es) |
| CA (2) | CA983850A (es) |
| DD (2) | DD96144A5 (es) |
| DE (2) | DE2163055A1 (es) |
| DK (2) | DK130389B (es) |
| ES (2) | ES398109A1 (es) |
| FR (2) | FR2123278B1 (es) |
| GB (1) | GB1370904A (es) |
| HU (2) | HU162347B (es) |
| IE (2) | IE35910B1 (es) |
| LU (1) | LU64664A1 (es) |
| NL (2) | NL7117404A (es) |
| NO (2) | NO135891C (es) |
| SE (2) | SE391286B (es) |
| ZA (2) | ZA718326B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917894A (en) * | 1988-06-29 | 1990-04-17 | Beecham Inc. | Rapid-onset long-duration oral anesthetic composition |
| AU6883798A (en) * | 1997-04-02 | 1998-10-22 | Regents Of The University Of California, The | Method of anesthesia |
| WO1998051290A2 (en) * | 1997-05-16 | 1998-11-19 | Children's Medical Center Corporation | Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent |
| EP2394646B1 (en) | 2006-03-27 | 2018-07-25 | Wex Medical Limited | Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy |
| US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
| CA3018668C (en) | 2013-03-15 | 2021-04-13 | The Children's Medical Center Corporation | Neosaxitoxin combination formulations for prolonged local anesthesia |
-
1971
- 1971-12-07 SE SE7115654A patent/SE391286B/xx unknown
- 1971-12-07 SE SE7115655A patent/SE391127B/xx unknown
- 1971-12-10 NO NO4557/71A patent/NO135891C/no unknown
- 1971-12-10 NO NO4558/71A patent/NO135892C/no unknown
- 1971-12-13 ZA ZA718326A patent/ZA718326B/xx unknown
- 1971-12-13 ZA ZA718327A patent/ZA718327B/xx unknown
- 1971-12-14 DK DK609571AA patent/DK130389B/da unknown
- 1971-12-16 BE BE776769A patent/BE776769A/xx unknown
- 1971-12-16 BE BE776768A patent/BE776768A/xx unknown
- 1971-12-16 HU HUAA688A patent/HU162347B/hu unknown
- 1971-12-16 HU HU71AA689A patent/HU162185B/hu unknown
- 1971-12-17 AT AT1084971A patent/AT310939B/de not_active IP Right Cessation
- 1971-12-17 CA CA130,377A patent/CA983850A/en not_active Expired
- 1971-12-17 AT AT1084871A patent/AT310938B/de not_active IP Right Cessation
- 1971-12-17 CA CA130,378A patent/CA986012A/en not_active Expired
- 1971-12-17 FR FR7145543A patent/FR2123278B1/fr not_active Expired
- 1971-12-17 NL NL7117404A patent/NL7117404A/xx not_active Application Discontinuation
- 1971-12-17 DK DK619971A patent/DK131606C/da active
- 1971-12-17 NL NL7117401A patent/NL7117401A/xx unknown
- 1971-12-17 GB GB5865871A patent/GB1370904A/en not_active Expired
- 1971-12-17 DD DD159910A patent/DD96144A5/xx unknown
- 1971-12-17 DD DD159688A patent/DD96400A5/xx unknown
- 1971-12-17 FR FR7145542A patent/FR2123277B1/fr not_active Expired
- 1971-12-18 ES ES398109A patent/ES398109A1/es not_active Expired
- 1971-12-18 DE DE19712163055 patent/DE2163055A1/de active Pending
- 1971-12-18 ES ES398108A patent/ES398108A1/es not_active Expired
- 1971-12-18 DE DE2163054A patent/DE2163054C3/de not_active Expired
- 1971-12-20 BR BR8428/71A patent/BR7108428D0/pt unknown
- 1971-12-20 AU AU37100/71A patent/AU465875B2/en not_active Expired
- 1971-12-20 IE IE1610/71A patent/IE35910B1/xx unknown
- 1971-12-20 IE IE1611/71A patent/IE35937B1/xx unknown
- 1971-12-20 BR BR8429/71A patent/BR7108429D0/pt unknown
-
1972
- 1972-01-26 LU LU64664D patent/LU64664A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gutmann et al. | Pathophysiologic aspects of human botulism | |
| EP0065747B1 (de) | Nonapeptid zur Behandlung von Suchtmittelentzugserscheinungen | |
| Ambache et al. | The effect of muscarine on perfused superior cervical ganglia of cats | |
| US4022899A (en) | Synergistic local anesthetic compositions | |
| US4029793A (en) | Synergistic local anesthetic compositions | |
| US3966934A (en) | Synergistic local anesthetic compositions | |
| NO135892B (es) | ||
| Bose et al. | Chemical and pharmacological studies on Argemone mexicana | |
| Gertner | The effect of compound 48/80 on ganglionic transmission | |
| Ogura et al. | Comparative pharmacological actions of ciguatoxin and tetrodotoxin, a preliminary account | |
| Scaer et al. | Effect of guanidine on the neuromuscular block of botulism | |
| Shaw et al. | Benzyldimethylbufotenin, a powerful antimetabolite of serotonin | |
| Goetz et al. | Biological neurotoxins | |
| DE2221281C3 (de) | Pharmazeutische Zubereitungen mit entzündungshemmender und analgetischer Wirkung | |
| Quilliam | DI-ISO Propyleluorophosphonate (DFP): Its Pharmacology and its Therapeutic uses in Glaucoma and Myasthenia Gravis | |
| MASON et al. | A comparison of the rate of absorption from normal and burned tissues | |
| Carpenter et al. | Inactivation of Toxins of Staphylococcus aureus and Clostridium welchii in vitro by Sulfanilamide. | |
| DE1667891B2 (de) | Verwendung von Ribonuclease bei der Schmerzbekämpfung | |
| US2807567A (en) | Preparation for the treatment of allergic diseases | |
| Strover | Snakebite and its treatment | |
| EA199901103A1 (ru) | Антивирусный препарат для инъекций | |
| Ivins et al. | Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin | |
| Osman et al. | Neuromuscular blocking activity of snake (Naja melanoleuca, Hallowel) venom | |
| Chopra et al. | The Venom of Indian Cobra (Naja Naja) in Certain Painful Conditions | |
| NZ239601A (en) | Use of n-acetyl neuraminic acid for treating kidney diseases |